Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Crit Care Med. 2021 May 1;49(5):828–837. doi: 10.1097/CCM.0000000000004891

Table 2.

Exposure and outcomes.

Variable Overall (n=4,172) ATACH-2 (n=905) ERICH (n=2521) FAST (n=746)
Hemoglobin (g/dL), mean (SD) 13.84 (1.91) 14.26 (1.73) 13.63 (2.02) 14.03 (1.62)
ICH volume (mL), mean (SD) * 19.99 (23.88) 13.70 (12.05) 21.39 (26.14) 22.88 (25.35)
Hematoma expansion, n (%) 781 (24.0) 195 (24.3) 370 (21.5) 216 (29.9)
Poor outcome , n (%) 1940 (46.5) 346 (38.2) 1235 (49.0) 359 (48.1)
Death, n (%) 770 (18.5) 66 (7.3) 554 (22.0) 150 (20.1)

Abbreviations: ATACH-2=Antihypertensive Treatment of Acute Cerebral Hemorrhage-II trial. ERICH=Ethnic/Racial Variations of Intracerebral Hemorrhage study. FAST=Recombinant Factor VIIa in Acute Intracerebral Hemorrhage trial. ICH=Intracerebral hemorrhage.

*

Missing data for baseline ICH volume = 92.

Poor outcome defined as modified Rankin Scale ≥ 4 at 3-month follow-up.